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Introduction: High-dose, post-transplantation cyclophos-
phamide (PTCy) is effective as single-agent graft-versus-host
disease (GVHD) prophylaxis after myeloablative conditioning
(MAC) and human leukocyte antigen (HLA)-matched-related
or -unrelated allogeneic bone marrow transplantation
(alloBMT), producing grade III-IV acute GVHD and chronic
GVHD rates of approximately 10-15% each. However, it is
unknown whether plasma-derived proteomic biomarkers
previously established using other transplantation platforms
are applicable to PTCy-treated patients.
Methods: Plasma was obtained from the peripheral blood of
100 adult patients, 70 of whom received busulfan/ﬂudar-
abine MAC and 30 of whom received busulfan/cyclophos-
phamide MAC, at month 1 and month 2-3 post-transplant.
Twelve healthy controls were used as a comparative group.
Plasma was analyzed using ELISA for interleukin-2 receptor
alpha (IL-2ra), IL-6, tumor necrosis factor receptor-1 (TNFR-
1), elaﬁn, regenerating islet-derived 3-alpha (REG3a), sup-
pression of tumorigenicity 2 (ST2), and chemokine (C-X-C
motif) ligand 9 (CXCL9).
Results: Plasma levels of 6 of the 7 putative biomarkers were
signiﬁcantly elevated (p<0.0001) in patients at 1 month
post-transplant compared with healthy controls; only elaﬁn
levels were similar between patients and controls. Plasma
levels of IL-2ra (p¼0.038), CXCL9 (p¼0.0003), and IL-6
(p¼0.032) at 1 month post-transplant were elevated in pa-
tients who would subsequently develop grade II-IV acute
GVHD. There also was a tendency of a relationship (p¼0.06)
between elevated elaﬁn levels at 1 month post-transplant
and grade II-IV acute GVHD development. None of the 7
biomarkers at post-transplant month 1 was prognostic of
chronic GVHD development. However, elevated REG3a levels
at month 2-3 were prognostic of the subsequent develop-
ment of chronic GVHD (p¼0.027). Elevations in 4 of the 7
biomarkers (IL-2ra, p¼0.014; IL-6, p¼0.024; TNFR-1,
p¼0.033; and ST-2, p¼0.0032) were predictive of non-
relapsemortality (NRM). Levels of the 7 biomarkers atmonth
1 were not predictive of permanent cessation of immuno-
suppressive therapy for GVHD by 1 year post-transplant.
Conclusion: Levels of all 7 tested biomarkers at month 1 or
month 2-3 post-transplant were prognostic for the occur-
rence of acute GVHD, chronic GVHD, and/or NRM in patients
treated with PTCy as single-agent GVHD prophylaxis after
MAC and HLA-matched-related or -unrelated alloBMT.
Testing of these biomarkers at earlier post-transplant time
periods or at patient-speciﬁc time points such as initiation of
treatment for GVHD may have added clinical utility in the
care of PTCy-treated patients.487
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The leukocyte adhesion molecule DNAM-1, also known as
CD226, is constitutively expressed of most CD4+ T cells, CD8+
T cells and natural killer (NK) cells. The poliovirus receptor
CD155, which is expressed on both hematopoietic and non-
hematopoietic cells, is a ligand for DNAM-1 and TIGIT. Upon
ligand binding, DNAM-1 mediates an activating signal in T
cells and NK cells. TIGIT acts as a marker for regulatory T cell
(Treg) subset and contributes to the Treg-mediated sup-
pression. We have recently demonstrated a critical role of
DNAM-1 on donor T cells in the development of acute GVHD
in a mouse model (Nabekura, et al, PNAS, 2010, 2011). Recent
reports also showed that DNAM-1 on donor cells promoted
acute GVHD in a CD4+ T cell-dependent manner via the in-
hibition of donor Treg expansion. Here, we found total body
irradiation upregulated CD155 expression on recipient’s
dendritic cell. Therefore, we examined the role of CD155
expressed on host cells in the development of acute GVHD by
using CD155-deﬁcient mice.
Lethally irradiated CB6F1 wild type (WT) or Cd155-/- mice
were transplanted with 5 x 106 bone marrow (BM) cells
together with 2 x 106 splenic T cells derived from C57BL/6
mice. Cd155-/- recipient mice showed body weight loss
signiﬁcantly greater than did WT mice after transplantation
(P < 0.05). Furthermore, Cd155-/- mice showed signiﬁcantly
shorter survival than WT mice (P < 0.01). Similar results
were obtained in an acute GVHDmodel (C57BL/6/BALB/c, P
< 0.05). Further analyses revealed that Cd155-/- recipient
mice showed decreased donor-derived Treg cell population,
compared with WT recipient mice (P < 0.01). Depletion of
Treg cells from transplanted splenic T cells resulted in com-
parable body weight loss and mortality between WT and
Cd155-/- recipient mice after transplantation. These results
suggest that host CD155 regulates the number of Treg cells
and attenuated the development of acute GVHD.
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Background: Unrelated cord blood transplantation (UCBT)
has increasingly been performed. Because cord blood units
Abstracts / Biol Blood Marrow Transplant 21 (2015) S322eS354S336contain a relatively low number of T cells with a higher
percentage of naive T cells than peripheral blood stem cells,
the presence or strength of the graft-versus-leukemia (GVL)
effect has been controversial. Using Japanese registry data,
we analyzed the impact of acute and chronic graft-versus-
host disease (GVHD) on outcomes after single UCBT.
Methods: We analyzed patients with acute leukemia or
myelodysplastic syndrome who underwent the ﬁrst UCBT (n
¼ 3,224) between 2000 and 2012 in Japan. The effect of acute
GVHD (aGVHD) on overall mortality, relapse, and non-
relapse mortality (NRM) was analyzed after adjusting for
other signiﬁcant variables among the engrafted patients,
whereas the effect of chronic GVHD (cGVHD) was analyzed
among the engrafted patients who survived without relapse
for at least 100 days. The occurrence of GVHD was treated as
a time-dependent covariate.
Results: The occurrence of grade 3 or 4 (G3-4) aGVHD was
signiﬁcantly associated with a higher risk of NRM (hazard
ratio [HR] 3.08, P < 0.001) than the occurrence of G0-1
aGVHD, in both the standard- and high-risk groups. The
occurrence of G2 or G3-4 aGVHD, as compared with G0-1
aGVHD, was signiﬁcantly associated with a low relapse rate
(G2 aGVHD: HR 0.80, P ¼ 0.003; G3-4 aGVHD: HR 0.71, P ¼
0.005). These resulted in the signiﬁcant association between
G2 aGVHD and low mortality (HR 0.79, P < 0.001), and G3-4
aGVHD and high mortality (HR 1.70, P < 0.001), as compared
with G0-1 aGVHD. The association between G3-4 aGVHD and
high mortality was stronger in the standard-risk group (HR
2.46, P < 0.001) than in the high-risk group (HR 1.40, P <
0.001). The occurrence of extensive cGVHD was associated
with a low relapse rate as comparedwith no cGVHD (HR 0.77,
P ¼ 0.046). The effect of limited cGVHD was signiﬁcant only
in the high-risk group (standard-risk: HR 1.07, P ¼ 0.673;
high-risk: HR 0.65, P ¼ 0.007). The occurrence of extensive
chronic GVHD was signiﬁcantly associated with high NRM
only in the standard-risk group (standard-risk, HR 1.46, P ¼
0.037; high-risk: HR 0.93, P ¼ 0.701). These resulted in the
signiﬁcant association between limited cGVHD and low
mortality in both groups, whereas extensive cGVHD was
associated with low mortality only in the high-risk group.
Conclusions: Similar to transplantations from a matched
sibling or an unrelated donor, G3-4 aGVHD should be pre-
vented because of its associated high overall and non-relapse
mortality rates, although acute GVHD was associated with
low relapse rates. Extensive cGVHD should be prevented
particularly in the standard-risk group because of its asso-
ciated high NRM. In the high-risk group, cGVHD was asso-
ciated with low relapse rates. The signiﬁcant association
between aGVHD or cGVHD and a low relapse rate supports
the presence of GVL effect in the UCBT even in the high-risk
group.Figure. Failure free survival in patients with late acute GVHD489
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Background: Late acute (LA) graft vs. host disease (GVHD) is
persistent, recurrent or new onset acute GVHD symptoms
more than 100 days after hematopoietic cell transplantation
(HCT). The aim of this analysis is to describe the onset,
course, and the morbidity and mortality associated with LA
GVHD.
Methods: A prospective cohort of patients was enrolled as
part of an observational study of immunemediated disorders
after HCTwithin the Chronic GVHD Consortium at 13 centers.
Patients with previous diagnosis of LA or chronic GVHD prior
to enrollment were excluded.
Results: Out of 913 patients in the study, 85 developed LA
GVHDwith a cumulative incidence of 11% at 2-year after HCT
(2-persistent, 40-recurrent and 43 de-novo). Median agewas
53.2 years, 70% received URD transplants, and graft source
was peripheral blood in 87%. 44% received myeloablative
conditioning, and 7% received ATG/Alemtuzumab. Median
time of onset for LA GVHD was 160 days (IQR 128-204) days
after HCT. Median follow-up for survivors after LA GVHD
diagnosis was 10.2 (range 0.7-25.9) months. 60% of patients
had biopsy proven LA GVHD. Single organ involvement at
diagnosis was seen in 59 patients (skin 39%, liver 14% and gut
47%), while 26 patients (31%) had2 organ involvement. 21%
of patients with liver GVHD had only transaminitis without
elevated bilirubin and hence were not included for acute
